You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed/refractory diffuse large B cell lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Mitoxantrone Hydrochloride Liposome Injection
  • Jinan, Shandong, China
    Affiliated Cancer Hospital of Shandong First Medical University
May 16, 2023

Relapsed/Refractory Diffuse Large B Cell Lymphoma Trial in Seoul (Glofitamab, Poseltinib, Lenalidomide)

Recruiting
  • Relapsed/Refractory Diffuse Large B Cell Lymphoma
  • Glofitamab, Poseltinib, Lenalidomide
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Nov 28, 2022

Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
  • (no location specified)
Sep 5, 2023

Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

Recruiting
  • Diffuse Large B-cell Lymphoma Recurrent
  • Diffuse Large B Cell Lymphoma Refractory
  • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 12, 2023

Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
Mar 23, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab vedotin and Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Diffuse Large B Cell Lymphoma Trial (Pembrolizumab, Rituximab, Ifosfamide)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Headington, Oxford, United Kingdom
  • +1 more
Nov 2, 2022

Chidamide in Recurrent and Refractory Diffuse Large b

Enrolling by invitation
  • Diffuse Large B-cell Lymphoma
  • Suzhou, Jiangsu, China
    Second Affiliated Hospital of Soochow University
Jan 9, 2023

Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory DLBCL Trial in United States (EZM0414)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  • Chevy Chase, Maryland
  • +10 more
Jan 12, 2023

Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)

Not yet recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • Shanghai, Shanhai, China
    Ruijin Hospital
Sep 29, 2023

DLBCL Trial (maplirpacept (PF-07901801), Glofitamab, Obinutuzumab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • maplirpacept (PF-07901801)
  • +2 more
  • (no location specified)
May 30, 2023

Relapsed/Refractory Diffuse Large B-cell Lymphoma Trial in China (ATG-010 and ATG-008)

Recruiting
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma
  • ATG-010 and ATG-008
  • Chongqing, Chongqing, China
  • +5 more
Sep 2, 2022

Diffuse Large B Cell Lymphoma Trial (anti-CD19 CAR NK cells)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • anti-CD19 CAR NK cells
  • (no location specified)
Dec 21, 2022

Diffuse Large B-cell-lymphoma Trial in Saint Louis, Cleveland (Venetoclax, Rituximab, Ifosfamide)

Active, not recruiting
  • Diffuse Large B-cell-lymphoma
  • Saint Louis, Missouri
  • +2 more
Nov 14, 2022

DLBCL Trial in San Juan (PF-07901801, Tafasitamab, Lenalidomide)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • San Juan, Puerto Rico
    Auxilio Mutuo Cancer Center
Jan 19, 2023

Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Low-Dose Decitabine plus anti-PD-1
  • Beijing, Beijing, China
    ChinaPLAGH
Apr 18, 2023

Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in Boston (Copanlisib, Venetoclax)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Duarte, California
  • +2 more
Nov 10, 2022

Molecular Classification of Relapsed/Refractory Diffuse Large

Completed
  • Lymphoma, Large B-Cell, Diffuse
  • Gene Expression Profiling
  • Gene expression profile
  • Shanghai, Shanghai, China
    Yian Zhang
Mar 31, 2022

Non-GCB/ABC DLBCL, With and Without MyD88 and/or CD79B Mutations Trial in Cleveland, Toledo (Mivavotinib)

Recruiting
  • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
  • With and Without MyD88 and/or CD79B Mutations
  • Evanston, Illinois
  • +6 more
Dec 12, 2022

Including miRNA-based Tumor Signatures in Diffuse Large B Cell

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • no intervention (observational study)
  • Napoli, Italy
  • +2 more
Feb 17, 2023

Diffuse Large B Cell Lymphoma, CAR-T, Radiotherapy Trial (ultra-fraction radiotherapy)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • ultra-fraction radiotherapy
  • (no location specified)
Aug 22, 2022

Diffuse Large B-cell Lymphoma Trial in Hangzhou, Ningbo (CD19-7×19 CAR-T combined with Tislelizumab)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • CD19-7×19 CAR-T combined with Tislelizumab
  • Hangzhou, Zhejiang, China
  • +1 more
Dec 12, 2022

Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma Trial in Dresden (MDC-CAR-BCMA001 (BCMA directed CAR

Not yet recruiting
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma
  • MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
  • Dresden, Germany
    Technische Universität Dresden, NCT/UCC, Early Clinical Trial Un
Apr 19, 2023

Diffuse Large B-cell Lymphoma Trial in Chapel Hill (Polatuzumab vedotin (PV), Rituximab, Hyaluronidase)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • Polatuzumab vedotin (PV)
  • +6 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Aug 9, 2022

Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

Active, not recruiting
  • Relapsed or Refractory Diffuse Large B-cell Lymphoma
  • BEBT-908 for injection
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023